



Late-Breaking Research To Expect at AIDS 2024

Take a look at some of the cutting-edge science highlights you can expect at the world's largest conference on HIV and AIDS.

July 8, 2024 By [International AIDS Society](#)

AIDS 2024, [the 25th International AIDS Conference](#), is just two weeks away! Take a look at some of the cutting-edge late-breaker research highlights you can expect at the world's largest conference on HIV and AIDS in Munich, Germany, and virtually.

[Register today](#) for AIDS 2024 from 22 to 26 July.

Some research highlights to expect at AIDS 2024

- The “next Berlin Patient”, a person experiencing sustained HIV remission without antiretroviral therapy after heterozygous CCR5 WT/delta32 allogeneic hematopoietic stem cell transplantation
- Important new data from the PURPOSE 1 trial, which found that twice-yearly injectable lenacapavir demonstrated 100% efficacy for HIV prevention in cisgender women
- Data from the PASO-DOBLE trial showing non-inferior efficacy and less weight gain when switching to DTG/3TC vs. BIC/FTC/TAF in virologically suppressed people living with HIV
- Results of a pilot randomized controlled trial of doxycycline pre-exposure prophylaxis (DoxyPrEP) for prevention of bacterial STIs in gay men and other men who have sex with men who are living with HIV

- New findings from DTG Resist, a large multi-country study on dolutegravir resistance patterns in central, eastern, southern and western Africa
- Insights from a first-of-its-kind survey showing significant HIV stigma and discrimination among European healthcare workers

All AIDS 2024 abstracts are now available in the [programme](#).

© 2024 Smart + Strong All Rights Reserved.

<https://www.poz.com/blog/latebreaking-research-expect-aids-2024>